HaiZheng Pharmaceutical: Fumarate Betadine raw material pharmaceuticals obtain approval notice.

Hai Zheng Pharmaceuticals announced that the company has recently received the "Chemical Active Pharmaceutical Ingredient Marketing Approval Notice" issued by the National Medical Products Administration for the approval of Fumaric Acid Bedaquiline raw materials. Fumaric Acid Bedaquiline is a dibenzylquinoline class anti-tuberculosis drug that is used to treat multidrug-resistant pulmonary tuberculosis in adults and adolescents. The global sales volume is estimated to be approximately 1482.57 kilograms in 2024, with domestic sales volume estimated to be around 151.08 kilograms. From January to March 2025, the global sales volume is estimated to be approximately 167.39 kilograms, with domestic sales volume estimated to be around 37.43 kilograms. The company has invested approximately 14.422 million RMB in the research and development of this drug project.